Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update is drawing significant interest across the industry.
Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical and preclinical programs advancing with defined milestonesAchieved fifth program milestone with Sanofi, totaling $134 million in payments to date; five Recursion discovery program packages have been accepted to date, establishing a growing joint portfolio of novel AI-driven small molecules for immunology and oncology$754 million of cash and cash equivalents; exceeded original cost savings guidance and now expect runway into early 2028 without additional financing, reflecting disciplined capital allocation alongside continued platform and program investment SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its fourth quarter and full year ending December 31, 2025.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Jane McDonald's 'lazy' fitness routine and why why yoga isn't for her
- Amazon’s Fire TV Stick 4K Plus gets a better interface and a 40 percent discount
- Josh Jacobs has ‘a lot of good years left,’ Packers general manager says
- I found an open-source Canva alternative, and it handles everything I actually need
Source: Original →